Table 1. Outcome measures between BM-MSC treatment groups and control groups.

	BM-MSCs	HBSS alone	Dermalfibroblasts	DeadBM-MSCs	No treatment	Significance (p)
Median day of disease onset (range)	12 (10–16)	12 (10–13)	12 (9–13)	12.5 (10–14)	12 (10–13)	0.76*
Median peak motor score (range)	5.5 (4–7)	5.5 (4–7)	5 (4–6)	5 (4–6)	6 (4–9)	0.3*
Median terminal motor score (range)	3 (0–5)	3 (0–4)	3.5 (2–5)	2 (0–5)	4 (2–6)	0.41*
Mean cumulative motor score (SD)	65.3 (18)	64.3 (17.6)	69.6 (13.3)	64.9 (21.9)	76.9 (12.4)	0.7§
Electrophysiology: ankle-foot median response score (range)	2/1 (0–4)/(0–4)	1/2 (0–3)/(0–4)	1/2 (0–3)/(0–4)	2/2 (0–4)/(0–2)	0/2 (0–2)/(0–3)	0.88*
Mean count of ED1+ cells per HPF (SD)	194 (81)	192 (68)	199 (84)	204 (86)	238 (63)	0.71§
Mean % of myelinated axons per HPF (SD)	25 (27)	27 (20)	27 (22)	31 (24)	9 (5)	0.34§

SD – standard deviation;

^*Kruskal-Wallis test;

^§one way ANOVA, Tukey post-test;

HPF – high power field;